The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).
 
Joseph McGuirk
Honoraria - AlloVir; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Consulting or Advisory Role - Allovir; EcoR1 Capital; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Speakers' Bureau - Kite/Gilead
Research Funding - AlloVir (Inst); Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Carlos R. Bachier
Employment - HCA Healthcare
Consulting or Advisory Role - crispr therapeutics (Inst); Juno/Celgene; Kadmon (Inst); Novartis; Viracyte (Inst); WUGEN, Inc. (Inst)
Research Funding - BMS (Inst)
 
Michael Russell Bishop
Employment - UnitedHealthcare
Honoraria - Celgene
Consulting or Advisory Role - AGIOS; Arcellx; Arcellx; Autolus; Bluebird Bio; BMS; crispr therapeutics; Iovance Biotherapeutics; Kite, a Gilead company; Novartis; Seagen
Speakers' Bureau - Agios; Bristol-Myers Squibb; Incyte; Kite, a Gilead company; Sanofi
Research Funding - Arcellx (Inst); crispr therapeutics (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - BMS; Kite/Gilead; Novartis
 
P. Joy Ho
No Relationships to Disclose
 
Hemant S. Murthy
Research Funding - crispr therapeutics (Inst)
 
Michael J. Dickinson
Honoraria - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Janssen; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Janssen; Novartis; Roche (I)
Speakers' Bureau - Novartis
Research Funding - Celgene (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche
 
Joseph E. Maakaron
Research Funding - Forty Seven (Inst)
 
Charalambos Andreadis
Employment - Genentech (I)
Stock and Other Ownership Interests - Roche/Genentech (I)
Consulting or Advisory Role - Atara Biotherapeutics; Epizyme; Gilead Sciences; Incyte; Karyopharm Therapeutics; Kite, a Gilead company; TG therapeutics
Research Funding - Amgen; Celgene; GlaxoSmithKline; Juno Therapeutics; Merck; Novartis
Travel, Accommodations, Expenses - Gilead Sciences; Kite, a Gilead company
 
Armin Ghobadi
Honoraria - Kite, a Gilead company
Consulting or Advisory Role - Amgen; Celgene; Kite, a Gilead company; WUGEN, Inc.
Speakers' Bureau - Kite, a Gilead company
Research Funding - Amgen; Kite, a Gilead company
 
Edmund K. Waller
Employment - Cambium Medical Technologies
Leadership - CAMBIUM MEDICAL TECHNOLOGIES; CAMBIUM MEDICAL TECHNOLOGIES; CAMBIUM MEDICAL TECHNOLOGIES
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; CAMBIUM MEDICAL TECHNOLOGIES; Cerus; Chimerix; Chimerix
Honoraria - Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Partners; Pharmacyclics; Verastem
Consulting or Advisory Role - Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Partners Healthcare; Pharmacyclics; Verastem
Research Funding - Amgen; Juno Therapeutics; Novartis; Partners Healthcare; Partners Healthcare; Verastem
Patents, Royalties, Other Intellectual Property - Receive Royalties from patent on preparing platelet lysate that has been licensed to Cambium Medical Technologies
Travel, Accommodations, Expenses - Pharmacyclics
 
Mark Daniel Benton
Employment - CRISPR Therapeutics
Stock and Other Ownership Interests - CRISPR Therapeutics
Patents, Royalties, Other Intellectual Property - I have patents pending relating my employment at CRISPR Therapeutics.
Travel, Accommodations, Expenses - crispr therapeutics
 
Susanna Suh
Employment - CRISPR Therapeutics
Stock and Other Ownership Interests - CRISPR Therapeutics
 
Huansheng Xu
Employment - crispr therapeutics
Stock and Other Ownership Interests - CRISPR Therapeutics
 
Ewelina Morawa
Employment - CRISPR Therapeutics
Leadership - CRISPR Therapeutics
Stock and Other Ownership Interests - CRISPR Therapeutics
Patents, Royalties, Other Intellectual Property - CRISPR Therapeutics
 
Farrukh Tauseef Awan
Consulting or Advisory Role - Abbvie; AstraZeneca; Blueprint Medicines; Celgene; Clinical Care Options; DAVA Pharmaceuticals; Genentech; Gilead Sciences; Janssen Oncology; Karyopharm Therapeutics; Medscape; MEI Pharma; Novartis; Pharmacyclics; Sunesis Pharmaceuticals; Verastem
Speakers' Bureau - Abbvie; AstraZeneca
Research Funding - Innate Pharma; Pharmacyclics
 
Paul Shaughnessy
Honoraria - Kite, a Gilead Company; Sanofi; Takeda
Speakers' Bureau - Kite, a Gilead Company; Sanofi; Takeda
 
Constantine Si Lun Tam
Honoraria - Abbvie; Beigene; Janssen-Cilag; Novartis; Pharmacyclics
Consulting or Advisory Role - Abbvie; BeiGene; Janssen; Loxo; Roche
Research Funding - Abbvie (Inst); Janssen-Cilag (Inst)
 
Nicolaus Kroeger
Consulting or Advisory Role - Celgene; Gilead Sciences; Jazz Pharmaceuticals; Neovii; Novartis; RIEMSER; Sanofi
Research Funding - Celgene (Inst); Neovii (Inst); Novartis (Inst); Riemser (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Jazz Pharmaceuticals; Neovii; Novartis; Sanofi
 
Richard T. Maziarz
Honoraria - Novartis; omeros; PACT Pharmaceuticals
Consulting or Advisory Role - Artiva; bms; incyte; Intellia Therapeutics; Kite, a Gilead company; Novartis
Patents, Royalties, Other Intellectual Property - ATHERSYS, INC shared patent re: use of mesenchymal stromal cells for treatment of GVHD
Travel, Accommodations, Expenses - Incyte; Kite, a Gilead company; Novartis